Targeting a neoantigen derived from a common TP53 mutation
(tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as , are not yet available. Here, we describe the identification of an antibody highly specific to the most common mutation (R175H, in which arginine at position 175 is repl...
Gespeichert in:
Veröffentlicht in: | Science (American Association for the Advancement of Science) 2021-03, Vol.371 (6533) |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!